Prevalence of Irritable Bowel Syndrome Based on Rome IV Criteria in Patients in Biochemical and Endoscopic Remission From Newly Diagnosed Inflammatory Bowel Disease: One- and Three-Year Results (the IBSEN III Cohort)
Inflammatory Bowel Diseases · 01.10.2025 · 31 (10) · 2704-2713
DOI: 10.1093/ibd/izaf047 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 10.03.2025. Verfasst von Bjorn Christian Olsen und 21 weiteren Autor:innen. Beteiligte Einrichtung: Telemark Hospital Trust, Department of Gastroenterology, Skien, Norway. Hauptthemen laut MEDLINE: Irritable Bowel Syndrome, Crohn Disease, Colitis, Ulcerative, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Telemark Hospital Trust, Takeda Pharmaceuticals, Pfizer.
Abstract (Originalsprache)
Background
Distinguishing irritable bowel syndrome (IBS) from inflammatory bowel disease (IBD) flare-ups is challenging. This study used objective remission markers to accurately determine IBS prevalence in a population-based cohort of patients with IBD.
Methods
Adults with ulcerative colitis and Crohn’s disease were recruited from the IBD in South-Eastern Norway III cohort study. Irritable bowel-like symptoms were assessed using the Rome IV criteria for patients in remission from IBD at 1- and 3-year follow-ups. Remission was defined objectively using the biochemical marker fecal calprotectin (FC) ≤ 250 µg/g, and comparisons to remission based on endoscopic indices were made at 1-year follow-up.
Results
Among patients with FC ≤ 250 µg/g, IBS prevalences were 21.9% (n = 62/283) and 16.1% (n = 49/304) at the 1- and 3-year follow-ups, respectively, which were higher than that in the Norwegian population (9.5%; P < .005). Of patients in endoscopic remission at 1-year follow-up, 19.2% (n = 43/224) reported IBS-like symptoms, which was not significantly different from IBS prevalence for patients with FC ≤ 250 µg/g. Irritable bowel syndrome was independently associated with substantial fatigue (odds ratio: 3.05 [95% CI, 1.48-6.27]) and female sex (odds ratio: 2.67 [95% CI, 1.34-5.32]) at the 1-year follow-up. Patients with IBS reported significantly reduced health-related quality of life (HRQoL) scores.
Conclusions
The prevalence of IBS among patients in remission from IBD was approximately twice as common as that in the Norwegian population. Irritable bowel syndrome was independently associated with substantial fatigue, female sex, and reduced HRQoL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Telemark Hospital Trust, Department of Gastroenterology, Skien, Norway.
- Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
- Department of Gastroenterology, Oslo University Hospital, Oslo, Norway.
- Department of Public Health, Institute of Health and Society, University of Oslo, Oslo, Norway.
- Vestfold Hospital Trust, Department of Gastroenterology, Tønsberg, Norway.
- Faculty of Health, Welfare and Organisation, Østfold University College, Fredrikstad, Norway.
ORCID-Profile: Bjorn Christian Olsen, Randi Opheim, Vendel A Kristensen, Marte Lie Høivik, Tone B Aabrekk, Ingunn Johansen, Kristina I Aass Holten, Vibeke Strande, May-Bente Bengtson, Petr Ricanek, Trond Espen Detlie, Asle W Medhus, Raziye Boyar, Roald Torp, Simen Vatn, Svein Oskar Frigstad, Jørgen Valeur, Tomm Bernklev, Lars-Petter Jelsness-Jørgensen, Gert Huppertz-Hauss
Förderung
- Telemark Hospital Trust
- Takeda Pharmaceuticals
- Pfizer
- Ferring Pharmaceuticals
- Tillotts Pharma
- Dam Foundation
- South-Eastern Health Authorities
Zitieren
APA
Olsen, B. C., Opheim, R., Kristensen, V. A., Høivik, M. L., Lund, C., Aabrekk, T. B., Johansen, I., Aass Holten, K. I., Strande, V., Glad, I. F., Bengtson, M. B., Ricanek, P., Detlie, T. E., Medhus, A. W., Boyar, R., Torp, R., Vatn, S., Frigstad, S. O., Valeur, J., …, & Huppertz-Hauss, G. (2025). Prevalence of Irritable Bowel Syndrome Based on Rome IV Criteria in Patients in Biochemical and Endoscopic Remission From Newly Diagnosed Inflammatory Bowel Disease: One- and Three-Year Results (the IBSEN III Cohort). Inflammatory Bowel Diseases, 31(10), 2704-2713. https://doi.org/10.1093/ibd/izaf047
Vancouver
Olsen BC, Opheim R, Kristensen VA, Høivik ML, Lund C, Aabrekk TB, et al. Prevalence of Irritable Bowel Syndrome Based on Rome IV Criteria in Patients in Biochemical and Endoscopic Remission From Newly Diagnosed Inflammatory Bowel Disease: One- and Three-Year Results (the IBSEN III Cohort). Inflammatory Bowel Diseases. 2025;31(10):2704-2713. doi:10.1093/ibd/izaf047
BibTeX
@article{Olsen2025,
author = {Olsen, Bjorn Christian and Opheim, Randi and Kristensen, Vendel A and Høivik, Marte Lie and Lund, Charlotte and Aabrekk, Tone B and Johansen, Ingunn and Aass Holten, Kristina I and Strande, Vibeke and Glad, Ida Frivold and Bengtson, May-Bente and Ricanek, Petr and Detlie, Trond Espen and Medhus, Asle W and Boyar, Raziye and Torp, Roald and Vatn, Simen and Frigstad, Svein Oskar and Valeur, Jørgen and Bernklev, Tomm and Jelsness-Jørgensen, Lars-Petter and Huppertz-Hauss, Gert},
title = {Prevalence of Irritable Bowel Syndrome Based on Rome IV Criteria in Patients in Biochemical and Endoscopic Remission From Newly Diagnosed Inflammatory Bowel Disease: One- and Three-Year Results (the IBSEN III Cohort)},
journal = {Inflammatory Bowel Diseases},
year = {2025},
volume = {31},
number = {10},
pages = {2704--2713},
doi = {10.1093/ibd/izaf047}
}
EUVIMED